Dr Alexandra Skeaping is Industry Partnerships and Commercialisation Executive for the Faculty of Medicine at Imperial College London.
![Alex Skeaping Image of Alex Skeaping](https://imperial.tech/wp-content/uploads/2021/09/Alex-Skeaping_m.png)
Dr Alexandra Skeaping
Industry Partnerships and Commercialisation Executive, Medicine
Alexandra's portfolio
![MicroRNA Biomarkers for ectopic or intrauterine pregnancy](https://imperial.tech/wp-content/uploads/2021/10/10439_header-web-600x400.jpg)
MicroRNA Biomarkers for ectopic or intrauterine pregnancy
MicroRNA are important gene regulators and their expression profiles change with pathophysiology, allowing their use as biomarkers. Imperial researchers have identified differential markers that can distinguish pregnancy of unknown location (PUL). Find out more
![Management of pre-term labour via an application for pathway selective EP2 agonist](https://imperial.tech/wp-content/uploads/2021/09/10457_header_web-600x400.jpg)
Management of pre-term labour via an application for pathway selective EP2 agonist
An EP2 receptor agonist with an application as a novel tocolytic for the management of pre-term labour. Find out more
![MicroRNA plasma markers for small-for-gestational-age (SGA) births](https://imperial.tech/wp-content/uploads/2021/09/9133_header_image-web-600x400.jpg)
MicroRNA plasma markers for small-for-gestational-age (SGA) births
Markers to determine the risk of SGA births based on miRNA plasma detected from maternal blood samples. Find out more
Sign up for updates
Sign up for monthly technology alerts via email, and find other ways to connect with us.